

1 **A live attenuated strain of HY9901 Δ vscB provides protection**
2 **against *Vibrio alginolyticus* in pearl gentian grouper**
3 **(♀ *Epinephelus fuscoguttatus* \times ♂ *Epinephelus lanceolatus*)**

4

5 Huanying Pang ^{ab,1*}, Yunsheng Chang^{ab,1}, Hongwei Zheng ^{ab}, Huiming Tan^{ab}, Shihui

6 Zhou ^{ab}, Fuyuan Zeng ^{ab}, Rowena Hoare^c, Sean J. Monaghan^c, Na Wang^d, Yu Ding^{ab**}

7 ^aCollege of Fishery, Guangdong Ocean University, Zhanjiang 524025, China

8 ^bGuangdong Provincial Key Laboratory of Pathogenic Biology and Epidemiology for

9 Aquatic Economic Animals, Zhanjiang 524025, China; Guangdong Key Laboratory of

10 Control for Diseases of Aquatic Economic Animals, Zhanjiang 524025, China

11 ^cInstitute of Aquaculture, University of Stirling, Stirling FK9 4LA, Scotland, UK

12 ^dChinese Academy of Inspection and Quarantine, Beijing, 100176, China

13

14

15 *Corresponding author: Huanying Pang

16 **Corresponding author: Yu Ding

17 Tel./fax: +86-759-2339319;

18 Address: College of Fishery, Guangdong Ocean University, No. 40 of East Jiefang Road,

19 Xiashan District, Zhanjiang, Guangdong Province, 524025, China;

20 E-mail: phying1218@163.com (H. Pang); dinv@foxmail.com(Y. Ding)

21 ¹ These authors contributed to the work equally and should be regarded as co-first

22 authors.

23

24 **ABSTRACT**

25 *Vibrio alginolyticus*, a bacterial pathogen in fish and humans, expresses a type III
26 secretion system (T3SS) that is critical for pathogen virulence and disease development.
27 In this study, the T3SS chaperone protein gene *vscB* was cloned from *V. alginolyticus*
28 wild-type strain HY9901. The results showed that the *vscB* gene has a length of 429 bp
29 and encodes 142 amino acids. The amino acid sequence homology comparison results
30 showed that VscB had the highest similarity with that of *Vibrio parahaemolyticus* VscB,
31 reaching 91%. The mutant strain HY9901 Δ *vscB* was constructed by the in-frame
32 deletion method. The HY9901 Δ *vscB* mutant showed an attenuated swarming
33 phenotype and a 23-fold decrease in virulence to pearl gentian grouper (♀ *Epinephelus*
34 *fuscoguttatus* \times ♂ *Epinephelus lanceolatu*). However, the HY9901 Δ *vscB* mutant
35 showed no difference in morphology, growth, biofilm formation and extracellular
36 protease (ECPase) activity. The results of antibiotic susceptibility testing showed that
37 the wild-type HY9901 is more sensitive to Doxycycline, Minocycline and Kanamycin
38 than in the HY9901 Δ *vscB* mutant. A total of 95 differentially expressed genes were
39 screened by transcriptome sequencing analysis of HY9901 and strain Δ *vscB*, revealing
40 57 genes up-regulated and 38 genes were down-regulated, respectively. qRT-PCR was
41 employed to analyze the transcription levels of T3SS-related genes showing that Δ *vscB*,
42 had decreased expression of *vopN* and *vscO* and increased expression of *hop*, *vscN*,
43 *vscK*, *vscL* and *vopS* compared to the wild strain. Finally, grouper vaccinated via

44 intraperitoneal (IP) injection with HY9901 Δ *vscB* had a high serum antibody titer with
45 a relative percent survival (RPS) of 77.6% following challenge with the wild-type
46 HY9901. Real-time qPCR assays showed that vaccination with HY9901 Δ *vscB*
47 enhanced the expression of immune-related genes, including MHC-I, IgM, and CD8 α
48 both in the liver and spleen, indicating that the mutant *V. alginolyticus* strain is able to
49 induce humoral and cell-mediated immune responses in pearl gentian grouper. These
50 results demonstrate that the HY9901 Δ *vscB* mutant could be used as an effective live
51 attenuated vaccine to combat *V. alginolyticus* infection in pearl gentian grouper.

52

53 **Keywords:** *Vibrio alginolyticus*; T3SS; *vscB*; live attenuated vaccine; pearl gentian
54 grouper

55

56

57

58

59

60

61

62

63

64

65

66 **Introduction**

67 In recent years, with the development of the aquaculture industry, vibriosis
68 outbreaks have become an important disease issue. *Vibrio spp.* pathogenic to aquatic
69 animals have caused huge economic losses to aquaculture (Lafferty et al., 2015;
70 Mahbub et al., 2011; Haldar, 2012) with *Vibrio alginolyticus* representing a common
71 serious threat to the health of cultured fish.

72 The pearl gentian grouper is a hybrid fish which is cultivated as a cross between
73 female grouper *Epinephelus fuscoguttatus* × male grouper *Epinephelus lanceolatu*. It is
74 a widely cultured marine fish with an important economic value and increasing market
75 demand in China, but development of the industry is restricted by vibriosis outbreaks
76 (Chen et al., 2019; Wei et al., 2020).

77 *V. alginolyticus* is mainly distributed in marine environments and is an
78 opportunistic pathogenic bacteria of marine organisms (López et al., 2009). Under
79 suitable conditions, *V. alginolyticus* can rapidly reproduce, out-competing other
80 colonizing bacteria becoming the dominant species, which following infection of the
81 mouth or wounds leads to death and large fish losses to industry (Sadok et al., 2013)..
82 At present, the main prevention and means of controlling vibriosis in grouper are
83 through use of chemical drugs and antibiotics (Zhao et al., 2010; Cai et al., 2007),
84 leading to significant increased antimicrobial resistance (AMR) to such drugs (Cai et
85 al., 2007; Chen et al., 2002; Wang et al., 2008). Vaccination provides a means of
86 prophylaxis without damaging the environment and mitigates issues relating to AMR.
87 Thus vaccine development for *V. alginolyticus* has become the focus of much research

88 for preventing vibriosis in grouper.

89 The type III secretory system (T3SS) plays an important role in the infection
90 process of *V. alginolyticus* (Bennett and Hughes, 2000; Yao et al., 2012; Galán and
91 Collmer, 1999; Cornelis and Van Gijsegem, 2000). Although there have been many
92 reports on the mechanism of T3SS effector proteins (Wattiau et al., 1994; Wattiau et al.,
93 1996), relatively few studies have elucidated the role of T3SS chaperone proteins,
94 which are required to maintain the effector protein stability in the bacterial cytoplasm
95 (Spaeth et al., 2009). Molecular chaperone proteins also assist the secretion or transport
96 of the T3SS effector proteins (Stebbins and Galán, 2001) and some can also be
97 transported into host cells and participate in host intracellular functions (Birtalan et al.,
98 2002; Day and Plano, 1998). VscB protein is an important component of the T3SS, and
99 is speculated to play an important role in host invasion. By functional domain prediction,
100 VscB is highly similar to Tir chaperone protein, which belongs to the Tir chaperone
101 protein (CesT) family. VscB belongs to chaperone protein (YscB) protein family. YscB
102 functions as a molecular chaperone for NosA protein, which gives *Yersinia pestis* the
103 ability to change host cell morphology (Day et al., 2003). It is reasonable to hypothesise
104 that VscB, as a molecular chaperone in the *V. alginolyticus* T3SS, plays an important
105 role in the regulation of T3SS.

106 Therefore, in this study, the gene encoding *vscB* of *V. alginolyticus* was cloned and
107 analysed by bioinformatics, providing evidence for the role of VscB in *V. alginolyticus*
108 T3SS. At the same time, the deletion strain of *vscB* was constructed to investigate the
109 molecular chaperone functions of VscB in *V. alginolyticus in vitro* and its role in

110 virulence. In addition, the *vscB* deletion strain of *V. alginolyticus* was tested as a
111 protective live attenuated vaccine in immunised pearl gentian grouper.

112

113 **Materials and methods**

114 **Bacterial strains, fish and culture conditions**

115 The bacterial strains and plasmids used in this work are listed in Table 1. *V.*
116 *alginolyticus* wild-type strain HY9901 was isolated from *Lutjanus erythropterus* (Cai et
117 al., 2007) and was utilized as the parent strain for constructing the mutant strain $\Delta vscB$
118 and the complementation strain C- $\Delta vscB$. *V. alginolyticus* was cultured on tryptic soy
119 broth (TSB, Huankai Co Ltd., Guangzhou, China) or on 1.5% TSB agar plates (TSA)
120 at 28°C. *Escherichia coli* strains were cultured in Luria-Bertani (LB, Huankai Co Ltd.,
121 Guangzhou, China) or on LB agar at 37 °C. When required, the appropriate antibiotics
122 were added: ampicillin (Amp, 100µg mL⁻¹); kanamycin (Km, 50µg mL⁻¹);
123 chloramphenicol (Cm, 25µg mL⁻¹).

124 Pearl gentian grouper (average weight 25.0 ± 2.0g) were obtained from a
125 commercial fish farm in Zhanjiang, China, and kept in seawater in a recirculation
126 system at 20-22°C for two weeks before the experiment. Fish were considered healthy
127 by sera agglutination and bacteriological recovery tests as described previously (Pang
128 et al., 2018).

129 Groupers were anaesthetized with tricaine methane sulfonate (MS222) (Kuer,
130 Anwei, China) before injections and sample collection. Animal experiments
131 complied with ethical standards and were approved by Guangdong Provincial Key

132 Laboratory of Pathogenic Biology and Epidemiology for Aquatic Economic Animals
133 Ethics Committee.

134 **Cloning and sequencing of the *vscB* gene from *V. alginolyticus* HY9901**

135 A pair of primers *vscB*-F1 and *vscB*-R1 were designed as shown in Table 2
136 according to the *V. alginolyticus* gene sequence (GenBank Number: GU074526). PCR
137 was performed in a Thermocycler (Bio-Rad, CA, USA) under the following optimized
138 amplification conditions: an initial denaturation at 95°C for 5 min, followed by 30
139 cycles of 95 °C for 30 s, 60 °C for 30 s and 68 °C for 30 s. 5 μ L of each amplicon was
140 examined on 1% agarose gels, stained with ethidium bromide. The PCR product was
141 recovered from the agarose gel to ligate into the pMD18-T vector and transformed into
142 *E. coli* DH5α (Table 1). The inserted fragment was sequenced by Sangon Biological
143 Engineering Technology Services Co., Ltd. (Shanghai, China). Similarity analyses of
144 the determined nucleotide sequences and deduced amino acid sequences were
145 performed by BLAST program ([http://blast.ncbi.nlm.nih.gov/ Blast.cgi](http://blast.ncbi.nlm.nih.gov/Blast.cgi)) and aligned
146 using the program Clustal-X (version 1.81). Protein analysis was conducted with
147 ExPASy tools (<http://expasy.org/tools/>). Location of the domain was predicted using
148 the InterProScan program (<http://www.ebi.ac.uk/Tools/pfa/iprscan/>).

149 **Construction of a $\Delta vscB$ and complementation of the mutant**

150 The $\Delta vscB$ mutant was constructed with allelic exchange mutagenesis. Firstly, two
151 specific pairs of primers were designed to obtain the *vscB* upstream homologous arm
152 fragment A (Primers: *vscB*-MF1 and *vscB*-MF2) and downstream homologous arm
153 fragment B (Primers: *vscB*-MR1 and *vscB*-MR2). Then, fragment A and B were used

154 as templates, and the AB fragments were fused together by overlapping PCR. The AB
155 fusion fragment was connected to the suicide vector pLP12, and the recombinant
156 product was transformed into *E. coli DH5α*. The positive clones were selected and the
157 recombinant plasmid PLP12-*vscB* was extracted. PLP12-*vscB* was transformed into *E.*
158 *coli β2163*. The positive clones were selected and used for the conjugation with *V.*
159 *alginolyticus*, and after undertaking homologous recombination twice, the $\Delta vscB$
160 mutant was successfully constructed with PCR identification (Primers: *vscB*-TF and
161 *vscB*-TR).

162 The *vscB* fragment (Primers: *vscB*-RF and *vscB*-RR) and pBAD33cm-rp4 vector
163 fragment (Primers: pBAD30-ZF and pBAD30-ZR) were amplified, connected and then
164 transformed into *E. coli DH5α*. The positive clones were selected (Primers: pBAD30-
165 mcf-TF and pBAD30-mcf-TR) and sequenced to confirm the successful construction
166 of *vscB* complementation strain (*C-vscB*).

167 **Characterization of the $\Delta vscB$**

168 The wild-type HY9901 strain and $\Delta vscB$ mutant was respectively cultured in TSA
169 at 28°C for 24 h. Cell morphology was then investigated by transmission electron
170 microscopy (TEM).

171 *Genetic stability of mutants HY9901 $\Delta vscB$*

172 HY9901 $\Delta vscB$ was inoculated onto a TSA plate and passed blindly for 30
173 generations. Its genetic stability was determined by PCR. Growth ability was measured
174 as previously described (Zhou et al., 2013). The wild-type HY9901 strain,
175 HY9901 $\Delta vscB$ and *C-vscB* were cultured in TSB for 24 h at 28 °C. The HY9901,

176 HY9901 Δ *vscB* and C-*vscB* were inoculated in TSB at the ratio of 1: 100 (OD₆₀₀ = 0.5),
177 determination of OD₆₀₀ was performed every 2 h, and repeated three times per group.

178 *Swarming motility*

179 Swarming motility was assayed using the method of Young et al (Young et al.,
180 1999) and initiated by spotting 2 mL of an overnight culture at the center of agar plates
181 containing 0.6% agar. The swarming diameter was measured after 24 h incubation. All
182 of experiments were performed in triplicate.

183 *Extracellular protease activity*

184 Extracellular protease (ECPase) activity was performed according to the method
185 of Windle and Kelleher (Windle and Kelleher, 1997). The wild-type strain HY9901,
186 HY9901 Δ *vscB* and C-*vscB* were each inoculated onto a TSA plate coated with aseptic
187 cellophane, cultured at 28°C for 24 h, washed with sterile PBS, centrifuged at 4 °C for
188 30 min, and the supernatant was filtered to obtain extracellular products. Inactivated
189 sample (supernatant was boiled for 10 min) was used as a blank control.

190 *Crystal violet ammonium oxalate staining*

191 With reference to the method (Kierek and Watnick, 2003), wild strains HY9901,
192 HY9901 Δ *vscB* and C-*vscB* (OD₆₀₀ = 0.5) were transferred to a 96-well plate (200
193 μ L/well, 6 replicate wells, negative control TSB) and the plates were incubated at 28 °C.
194 Samples were taken at 12 h, 24 h, 48 h and 72 h, methanol fixed for 20 min, then stained
195 with Crystal violet ammonium oxalate dye for 15 min. Finally, 95 % alcohol was then
196 added and incubated at room temperature for 30 min. OD₅₇₀ was determined by using
197 a Multimode Plate Reader.

198 *Confocal Laser Scanning Microscopy (LSCM)*

199 The wild strain HY9901 and the mutant strain HY9901 Δ *vscB* were diluted 50-fold,
200 added to a glass bottom culture dish(spec: type 28.2mm, class diameter 20mm) (Wuxi
201 NEST, Wuxi, China), and statically cultured in a 37 °C biochemical incubator for 24 h,
202 gently washed three times with physiological saline, and 10 % SYTO9 green added.
203 Incubation of bacteria with fluorescent dyes was carried out in the dark for 20 min,
204 bacteria were washed three times with saline, mounted in 40 % saline-glycerol and
205 observed by confocal microscopy. The excitation wavelength was 488 nm, scanned
206 from the bottom to the top of the biofilm, with Z-sections obtained 1 μ m apart. Biofilm
207 parameters - biomass and maximum thickness were determined.

208 *LD₅₀ determination*

209 The injection concentrations of wild-type strain HY9901 Δ *vscB* and *C-vscB* were
210 10^4 , 10^5 , 10^6 , 10^7 and 10^8 cfu / mL. In the experimental group, 100 μ L bacterial solution
211 was injected into each tail by intramuscular injection. The control group was injected
212 with 100 μ L of PBS in the same manner. Mortalities of experimental fish were recorded
213 over a 14 day period until the mortality rate was stable. The morbidity induced by *V.*
214 *alginolyticus* was determined, and the LD₅₀ of mutant and wild strain was calculated by
215 Koch method (Reed and Muench, 1938) with three replicates per group.

216 **Antibiotic susceptibility**

217 The susceptibility patterns of the HY9901, Δ *vscB* and *C-vscB* to 30 different
218 antibiotics were determined according to the disc diffusion method using TSA (Bauer
219 et al., 1966), and the diameters of the inhibition zones were measured using Vernier

220 calipers. Resistant, intermediate and susceptible phenotype determinations were based
221 on the manufacturer guidelines. The strains were inoculated onto TSA plates and
222 allowed to absorb onto agar for 10 min, and antibiotic discs were added after 24 h of
223 incubation at 28 °C (Zhou et al., 2020).

224 **Expression Analysis of T3SS-related genes**

225 T3SS secretion was induced by Dulbecco's Modified Eagle Medium (DMEM)
226 media (Nydam et al., 2014; Li et al., 2016), and strains HY9901 and HY9901 Δ *vscB*
227 were cultured for 12 h at 28 °C. The primers for T3SS related genes are shown in (Table
228 2). The genes in this study were *hop* (Guillon et al., 2010), *vopN*, *vscN* (Yuan et al.,
229 2016), *vscO* (Zhou et al., 2013), and *vopS*, *vscL*, *vscK* (Nguyen et al., 2000). According
230 to the experimental method of Li et al. (Li et al., 2016), total RNA was extracted using
231 TRIzol Reagent (Invitrogen, USA) according to the manufacturer's instructions
232 respectively. The first-strand cDNA was synthesized from the DNase I (Takara, Japan)
233 treated total RNA using the Reverse Transcriptase M-MLV (Takara, Japan) according
234 to the manufacturer's protocol. The PCR assay was performed in a 25 μ L reaction
235 volume containing 0.5 μ L of each primer (10 μ M), 2 μ L of diluted cDNA (1:10), 12.5
236 μ L of 2 x TransStartTM Green qPCR SuperMix (TransGen, Beijing) and 9.5 μ L sterile
237 water. The PCR amplification procedure was carried out at 95 °C for 4 min, followed
238 by 35 cycles of 95 °C for 20s, 50 °C for 20s and 72 °C for 20s. Melt curve analyses of
239 amplification products were performed at the end of each PCR reaction. Samples were
240 run in triplicate on the Bio-Rad iQ5 Real-time PCR System (Bio-Rad, CA, USA). 16S
241 rRNA was used as an internal control. Each of the samples included six independent

242 individuals, respectively, to eliminate individual differences. All primer pairs amplified
243 a single PCR product which was analyzed in triplicate using the appropriate T_m value
244 by agarose gel electrophoresis and melting curve analysis.

245 **Transcriptome sequencing**

246 For transcriptome sequencing, HY9901 and $\Delta vscB$ cells were cultured in DMEM
247 media (initial OD₆₀₀ of 0.01) at 28 °C for 12 h., The bacterial cells were harvested and
248 then dissolved in TRIzol (Takara Bio, Inc.). The series of experiments, including mRNA
249 extraction, RNA fragmentation, cDNA synthesis and RNA-Seq library construction,
250 were conducted by Novogene Co., Ltd.

251 **Investigation of the viability of HY9901 $\Delta vscB$ in vivo post vaccination**

252 The pearl gentian grouper injected intraperitoneally with 100 μ L 1×10^5 cfu mL⁻¹
253 ¹HY9901 $\Delta vscB$ extended to 7 days post vaccination. The organs including spleen and
254 head-kidney were aseptically collected from day 1 to day 7. All the samples were
255 weighed and homogenized in 1 ml PBS. The homogenates were serially diluted and
256 plated in triplicate onto TCBS plates and incubated at 28 °C for 18 h. The bacteria
257 counts were calculated by dividing the weights of the tissues and from the mean of three
258 samples.

259

260 **Pearl gentian grouper vaccination and bacterial challenge**

261 Groupers were randomly divided into 2 groups with 85 fish in each group, and the
262 water temperature was regulated at 26 °C using heating rods. The experimental vaccine
263 group injected intraperitoneally with 100 μ L $\Delta vscB$ bacterium solution (1×10^5

264 CFU/mL) per tail. The control group was injected intraperitoneally with 100 μ L PBS
265 per tail.

266 Four weeks post immunization, groupers (n=30) were anesthetized and challenged
267 separately by IP inoculation of 100 μ L 1×10^8 cfu mL⁻¹ of *V. alginolyticus* HY9901. The
268 number of dead fish after HY9901 challenge was recorded for 16 days until the
269 mortality rate stabilized. The dead fish were sampled and the bacteria in the diseased
270 fish tissues were isolated. The bacteria were cultured on a TSA plate and identified by
271 16s rDNA sequencing to determine whether the death of grouper was caused by the
272 challenge of *V. alginolyticus* HY9901.

273 The relative percent survival (RPS) was calculated according to the following
274 formula: RPS (%) = (1-immunized group mortality / control group mortality) \times 100%.

275 **Immune Gene Expression of grouper Induced by HY9901 Δ *vscB* Vaccine**

276 Liver and spleen samples were taken from three fish from each group (state
277 groups), 1 day prior to challenge. Immune-related gene expression levels were detected
278 with real-time qPCR. Primers for IL-1 β , MHC-1, IgM, TNF- α and CD8 α are shown in
279 Table 2, and β -actin was used as an internal reference gene. The procedures of RNA
280 extraction, cDNA synthesis, and real-time qPCR for analysis of immune gene
281 expression were carried out as previously described (Li et al., 2016).

282 **Statistical Analysis**

283 Statistical analyses were performed using SPSS 17.0 (SPSS Inc., USA). Using the
284 Student's t-test Group differences (strains HY9901 and HY9901 Δ *vscB*) were
285 determined by Duncan's test. ** indicates highly significant difference compared with

286 the control group ($p < 0.01$). * indicates significant difference compared with the
287 control group ($p < 0.05$).

288

289 **Results**

290 **Cloning, mutagenesis and complementation of *vscB* in *V. alginolyticus* HY9901**

291 The *vscB* gene consisted of an open reading frame of 429 bp encoding 142 amino
292 acids with a predicted molecular mass of 16.402 kDa and a theoretical isoelectric point
293 of 5.48. The nucleotide sequence of HY9901 *vscB* was deposited in the GenBank
294 database under the accession number MG905226 (**Fig.1**). Blast analysis (NCBI) of the
295 deduced amino acid of *vscB* indicated that it has 60-91% identity with other *Vibrio spp.*
296 and it shared the highest homology to *vscB* of *V. parahaemolyticus* (91%) (**Fig. 2**).

297 To understand possible roles of VscB in *V. alginolyticus*, an unmarked *vscB*
298 deletion mutant was constructed by using overlap PCR and a double-selection strategy.
299 HY9901 Δ *vscB* was confirmed by PCR by generating a fragment of 1396 bp (**Fig. 3A**).
300 C-*vscB* was confirmed by PCR by generating a fragment of 587 bp (**Fig. 3B**).

301

302 **Characterization of the Δ *vscB***

303 Morphology was observed by transmission electron microscopy (TEM), and
304 there was no discernible morphological difference among HY9901, Δ *vscB* and C-*vscB*
305 (**Fig. 4**).

306 After 30 generations of continuous blind transmission of mutant Δ *vscB* a fragment
307 of 974 bp was obtained by HY9901 Δ *vscB* (**Fig. 5**).

308 There were no significant differences between growth rates of wild-type strain

309 HY9901, HY9901 Δ *vscB* and C-*vscB* ($p > 0.05$) (**Fig. 6**). Also, no significant
310 differences were observed in biofilm formation in the HY9901, Δ *vscB* and C-*vscB*
311 strains ($p > 0.05$) (**Fig. 7**). The extracellular protease (ECPase) activity was not
312 significantly different in the HY9901, Δ *vscB* and C-*vscB* ($p > 0.05$) (**Table 3**). With
313 regards to swarming activity, the swarming circle of the wild strain HY9901 was 32.22
314 ± 0.07 mm, Δ *vscB* was 27.83 ± 0.06 mm, and C-*vscB* was 31.18 ± 0.06 mm (**Table 3**).
315 The swarming circle diameter of Δ *vscB* was smaller than that of wild strain HY9901
316 and C-*vscB*, indicating that the swarming ability was related to *vscB*. Grouper from
317 quarantined stocks recognized as disease free (Xu et al., 2011) were used (Sullivan and
318 Kim, 2008) to assess the virulence of the strain HY9901, Δ *vscB* and C-*vscB*. The
319 HY9901 Δ *vscB* mutant had an attenuated swarming phenotype and a 23-fold decrease
320 in virulence to grouper. ($p < 0.01$, **Table 3**). The results showed that the virulence of *V.*
321 *alginolyticus* Δ *vscB* was significantly reduced.

322

323 **Antibiotic susceptibility**

324 All the strains were susceptible to amikacin, minocycline, tetracycline, gentamicin
325 and doxycycline; and resistant to cefperazone, oxacillin, clindamycin, ceftazidime,
326 penicillin, ampicillin, ceftazidime, ceftazidime, cefazolin, ceftriaxone, cephadrine, piperacillin,
327 cefuroxime, SMZ/TMP, moxacin, and fuazolidone. Both wild and mutant strains were
328 susceptible to chloramphenicol, neomycin and resistant to erythromycin, but C-*vscB*
329 was susceptible to erythromycin and resistant to chloramphenicol and neomycin. The
330 wild and C-*vscB* were susceptible to kanamycin, the mutant Δ *vscB* was resistant to

331 kanamycin (**Table 4**).

332

333 **T3SS-related genes expression analysis**

334 As the *vscB* gene regulates T3SS-related transcription levels, qRT-PCR was
335 employed to analyze the transcription levels of T3SS-related genes including *vscL*,
336 *vscK*, *vopN*, *vscO*, *vscN*, *vopS* and *hop*. *vscL* and *vscK* are apparatus proteins, *vopS*,
337 *vopN*, *vscN* and *hop* are effector or regulatory proteins, *vscO* is a chaperone escort
338 protein. The results showed that compared with HY9901 wild type, HY9901 Δ *vscB*
339 decreased the expression of *vopN*, *vscO*, while increasing the expression of *vopS*, *vscK*,
340 *vscL*, *hop*, and *vscN*. (**Fig. 8**).

341

342 **Transcriptome sequencing analysis of HY9901 and strain Δ *vscB***

343 A total of 95 differentially expressed genes were screened by transcriptome
344 sequencing analysis of HY9901 and strain Δ *vscB*, among which 57 genes were up-
345 regulated and 38 genes were down-regulated, respectively (Table S1). GO analysis
346 showed that the differentially expressed genes of HY9901 and strain Δ *vscB* were
347 mainly associated with oxidation-reduction process, single-organism metabolic process
348 and oxidoreductase activity (**Fig. 9**).

349

350 **Investigation of the viability of HY9901 Δ *vscB* in vivo**

351 HY9901 Δ *vscB* was able to disseminate into but survive transiently in fish head-
352 kidney and spleen then was gradually eliminated from the host body (**Fig. 10**). The
353 highest bacterial number was detected in spleen on day 3, followed by the head-kidney.

354

355 **Vaccine efficacy**

356 The protective efficacy of $\Delta vscB$ was evaluated by challenging grouper with *V.*
357 *alginolyticus* wild strain 28 d after vaccinating fish with PBS or the $\Delta vscB$ strain. The
358 results showed that the survival rate (RPS) in the $\Delta vscB$ group was 77.6% (**Fig.11**. The
359 results indicated that $\Delta vscB$ had only minimal virulence and induced a protective
360 response in grouper thus potentiating it's use as an attenuated live vaccine.

361

362 **Immune gene expression of grouper induced by HY9901 $\Delta vscB$ vaccine**

363 The immune response of grouper immunized with the HY9901 $\Delta vscB$ live
364 attenuated vaccine was assessed by qPCR to analyze the transcriptional levels of pro-
365 inflammatory and immunoglobulin-related immune genes. The results showed that the
366 group vaccinated with the mutant strain HY9901 $\Delta vscB$ had significantly increased
367 expression of MHC-I α and CD8 α genes in the liver and spleen compared to control fish
368 injected with PBS ($p < 0.01$). (**Fig. 12**)

369

370 **Discussion**

371 The type III secretion system of *V. alginolyticus* is a determining factor in the
372 process of infecting the host cell. Molecular chaperones play an important role in this
373 system. The secretion of effector proteins required the assistance of chaperone proteins
374 to retain the secretory capacity of the effector protein (Day et al., 2003). *yscB* is the
375 chaperone of the effector *NosA* in *Yersinia*, whereby it can change the morphology of
376 host cell after invasion (Day et al., 2003), but little is known about the *vscB* of *V.*

377 *alginolyticus*.

378 In the current study, we knocked out the T3SS gene *vscB* of *V. alginolyticus*,
379 explored the physiology and pathogenicity of the mutant, and evaluated its efficacy as
380 a live attenuated vaccine. In the genetic stability test, the $\Delta vscB$ strain was still capable
381 of amplifying the upstream and downstream fusion fragments of *vscB* after 30
382 generations, indicating that the genetic information of the $\Delta vscB$ can be stably
383 transmitted to offspring.

384 Production of extracellular products (ECP) mainly including protease, hemolysin
385 and siderophore, are thought to be characteristics of virulent strains of *V. alginolyticus*
386 (Fletcher, 1977; Lee et al., 1997). Biofilm formation is a multicellular behavior by
387 which bacteria colonize the surface of host tissues, leading to resistance to antibiotics
388 and host immune responses (Parsek and Singh, 2003; Verstraeten et al., 2008).
389 Nevertheless, our results indicated that there was no significant difference between
390 HY9901 and $\Delta vscB$ in morphology, growth, biofilm, and ECPase activity. Therefore,
391 *vscB* may not be responsible for these characteristics in *V. alginolyticus*. The flagella
392 contributed to swarming motility and facilitated bacterial access to appropriate niches
393 inside the host after *Vibrio* infection (Watnick et al., 2001). Studies have shown that the
394 flagella is essential for virulence, flagellum formation, efficient motility and symbiotic
395 competence during initial squid light organ colonization by *Vibrio* (Millikan et al.,
396 2004). In the present study, the $\Delta vscB$ mutant of *V. alginolyticus* had suppressed
397 swarming motility. The results suggested that *vscB* is a positive contributor to swarming
398 motility in *V. alginolyticus* and might function indirectly through regulating the

399 expression level of flagella, however this needs further investigation. The LD₅₀ of
400 $\Delta vscB$ was 23.2 times lower than that of wild strain. These results indicated that the
401 *vscB* gene contributes to the pathogenesis of *V. alginolyticus*.

402 According to the experimental results, the mutant strain $\Delta vscB$ was more resistant
403 to drugs than the wild strain HY9901, so it could be speculated that the *vscB* gene might
404 be related to drug resistance genes.

405 Zhou et al. found that *sycD*, *vopB* and *vopD* mRNAs decreased significantly in the
406 $\Delta vscO$ mutant compared with the wild-type strain (Zhou et al., 2013). Chen found that
407 the expression levels of *vscX* mRNA in the deletion strain $\Delta vscO$ were significantly up-
408 regulated at a late growth stage (Chen et al., 2017). In this study, $\Delta vscB$ had decreased
409 expression of *vopN* and *vscO* and increased expression of *hop*, *vscN*, *vscK*, *vscL* and
410 *vopS*. These results suggested that T3SS-related genes could play an important role in
411 mediating these proteins and regulating the transcription of these T3SS genes to
412 maintain a suitable level of protein synthesis and secretion via an unclear mechanism.
413 However, the regulatory mechanism network of *V. alginolyticus* T3SS is still unknown
414 and its role in pathogenesis warrants further attention.

415 At present, there is no commercial Vibriosis vaccine for grouper in China,
416 although the disease has been causing great economic losses to the aquaculture industry
417 (Li et al., 2010; Xie et al., 2005). Virulence gene deletion is becoming a common
418 strategy for attenuated live vaccine development, which benefits from its low toxicity
419 and sustainable protection. In recent years, live attenuated vaccines have demonstrated
420 great potential in preventing and controlling lethal bacterial diseases (Pang et al., 2018;

421 Li et al., 2015; Wang et al., 2014). Pang et al. found that grouper vaccinated via IP
422 injection with HY9901 Δ *hop* induced a high antibody titer with a RPS value of 84%
423 after challenging with the wild type *V. alginolyticus* HY9901 (Pang et al., 2018). Chen
424 et al. showed that the Δ *acfA* mutant caused a high antibody titer with a RPS value of
425 81.1% after challenging with *V. alginolyticus* HY9901 in pearl gentian grouper (Chen
426 et al., 2019). Chen et al. also found that Δ *sodB* induced a high antibody titer and
427 provided valid protection with a RPS value of 86.5% without inducing clinical
428 symptoms after challenging with *V. alginolyticus* HY9901 (Chen et al., 2019). Zhang
429 et al. showed that the Δ *yscB* mutant elicited a higher antibody titer and provided
430 protective efficacy against both subcutaneous and intranasal *Y. pestis* challenge (Zhang
431 et al., 2013). In this study, the RPS of grouper vaccinated with Δ *vscB* mutant reached
432 77.6%, which was significantly higher than that of the control group. The results
433 showed that the Δ *vscB* mutant could provide effective protection against challenge with
434 *V. alginolyticus* and has the potential as an attenuated live vaccine.

435 It has already been confirmed that live attenuated vaccines can induce a more
436 robust humoral and cell-mediated immune response than killed bacteria (Killeen et al.,
437 2001). The increase of MHC-I α expression in the spleens was also found in pearl
438 gentian grouper vaccinated with a *V. alginolyticus* *acfA* mutant (Chen et al., 2019). IgM
439 gene expression can be induced by intraperitoneal injection with *Yersinia ruckeri* in
440 rainbow trout (Deshmukh et al., 2013). CD8 is the specific marker of cellular defense,
441 and is increased in fish vaccinated with an *Edwardsiella tarda* mutant in turbot (Xiao
442 et al., 2013). In this study, the elevated expression of immune-related genes (MHC-I α ,

443 IgM and CD8 α), confirmed the stimulation of innate and acquired immune responses
444 in pearl gentian grouper. Future work using immunohistochemical methods or flow
445 cytometry sorting rather than qPCR will further provide a deeper understanding of the
446 protective immune mechanisms of HY9901 $\Delta vscB$ in pearl gentian grouper or other fish.

447 In conclusion, we have successfully constructed an in-frame deletion strain of
448 HY9901 $\Delta vscB$ and investigated its biological characteristics and pathogenicity
449 revealing suppressed swarming motility and virulence despite stable morphology,
450 growth, biofilm and ECPase activity consistent with the wild-type strain. The *vscB* gene
451 regulates T3SS proteins and drug resistance genes, and a $\Delta vscB$ mutant strain provides
452 protection to immunized grouper. There was no significant difference between HY9901
453 and HY9901 $\Delta vscB$ in morphology, growth, biofilm, and ECPase activity. The $\Delta vscB$
454 mutant of *V. alginolyticus* had suppressed swarming motility. The LD₅₀ of
455 HY9901 $\Delta vscB$ was 23.2 times lower than that of wild strain. The *vscB* gene regulated
456 T3SS proteins and drug resistance genes. The $\Delta vscB$ mutant induced a high level of
457 protection against *V. alginolyticus* challenge. Taken together, the results enhance our
458 understanding of the role of *vscB* in the biology and pathogenicity of *V. alginolyticus*
459 and offer an insight into the development of a live attenuated vaccine for preventing
460 Vibriosis.

461

462 **Acknowledgments**

463 This work was supported by the National Natural Science Foundation of China (No.
464 32073015), Natural Science Foundation of Guangdong Province (No.

465 2021A1515011078), Innovation Program in Postgraduate Education of Guangdong
466 Ocean University (No. 201724), Undergraduate Innovation Team of Guangdong Ocean
467 University (No.CCTD201802), Innovation and Entrepreneurship Training Program for
468 College Students (No. CXXL2020131), Science and Technology Innovation
469 Cultivation Program for College Student (No. pdjh2021b0239).

470

471 **Competing interests**

472 The authors declare that there is no conflict of interest.

473

474 **References**

- 475 Bauer A.W., Kirby W.M., Sherris J.C., Turck M., 1966. Antibiotic susceptibility testing by a standardized
476 single disk method. *Am J Clin Pathol.* 45(4), 493-496.
- 477 Bennett J.C., Hughes C., 2000. From flagellum assembly to virulence: the extended family of type III
478 export chaperones. *Trends in microbiology.* 8(5), 202-204. [https://doi.org/10.1016/S0966-842X](https://doi.org/10.1016/S0966-842X(00)01751-0)
479 (00)01751-0.
- 480 Birtalan S.C., Phillips R.M., Ghosh P., 2002. Three-dimensional secretion signals in chaperone-effector
481 complexes of bacterial pathogens. *Molecular cell.* 9(5), 971-980. [https://doi.org/10.1016/s1097-](https://doi.org/10.1016/s1097-2765(02)00529-4)
482 2765(02)00529-4.
- 483 Cai S.H., Wu Z.H., Jian J.C., Lu Y.S., 2007. Cloning and expression of the gene encoding an extracellular
484 alkaline serine protease from *Vibrio alginolyticus* strain HY9901, the causative agent of vibriosis in
485 *Lutjanus erythropterus* (Bloch). *Journal of fish diseases.* 30(8), 493-500.
486 <https://doi.org/10.1111/j.1365-2761.2007.00835.x>.
- 487 Cai S.H., Wu Z.H., Jian J.C., Lu Y.S., 2007. Cloning and expression of gene encoding the thermostable
488 direct hemolysin from *Vibrio alginolyticus* strain HY9901, the causative agent of vibriosis of
489 crimson snapper (*Lutjanus erythropterus*). *Journal of applied microbiology.* 103(2), 289-296.
490 <https://doi.org/10.1111/j.1365-2672.2006.03250.x>.
- 491 Cai X.H., Wang B., Peng Y.H., Li Y., Lu Y.S., Huang Y.C., Jian J.C., Wu Z.H., 2017. Construction of a
492 *Streptococcus agalactiae* phoB mutant and evaluation of its potential as an attenuated modified live
493 vaccine in golden pompano, *Trachinotus ovatus*. *Fish & Shellfish immunology.* 63, 405-416.
494 <https://doi.org/10.1016/j.fsi.2016.11.050>.
- 495 Chen X.Y., Hu C.Q., Ren C.H., Chen C., 2002. Development, characterization and application of
496 monoclonal antibody against *Vibrio alginolyticus* lipopolysaccharide. *High Technol.* 12(11), 90-95.
- 497 Chen X.Y., Li j., Pang H.Y., Chang Y.S., Huang Y.C., Wu Z.H., Jian J.C., 2017. Molecular Cloning,
498 Bioinformatics Analysis and Expression Analysis of Type III Secretion System(T3SS) Injectosome

-
- 499 Gene *vscX* from *Vibrio alginolyticus*. *Agricultural Biotechnology*. 6(01), 41-45.
500 <https://doi.org/10.19759/j.cnki.2164-4993.2017.01.010>.
- 501 Chen Y.Y., Cai S.H., Jian J.C., 2019. Protection against *Vibrio alginolyticus* in pearl gentian grouper (♀
502 *Epinephelus fuscoguttatus* × ♂ *Epinephelus lanceolatus*) immunized with an *acfA*-deletion live
503 attenuated vaccine. *Fish & Shellfish Immunology*. 86, 875-881. [https://doi.org/](https://doi.org/10.1016/j.fsi.2018.12.030)
504 [10.1016/j.fsi.2018.12.030](https://doi.org/10.1016/j.fsi.2018.12.030).
- 505 Chen Y.Y., Wu F.L., Pang H.Y., Tang J.F., Cai S.H., Jian J.C., 2019. Superoxide dismutase B (*sodB*), an
506 important virulence factor of *Vibrio alginolyticus*, contributes to antioxidative stress and its potential
507 application for live attenuated vaccine. *Fish & shellfish immunology*. 89, 354-360.
508 <https://doi.org/10.1016/j.fsi.2019.03.061>.
- 509 Cornelis G.R., Van Gijsegem F., 2000. Assembly and function of type III secretory systems. *Annual*
510 *Reviews in Microbiology*. 54(1), 735-774. <https://doi.org/10.1146/annurev.micro.54.1.735>.
- 511 Day J.B., Ferracci F., Plano G.V., 2003. Translocation of YopE and YopN into eukaryotic cells by *Yersinia*
512 *pestis* yopN, *tyeA*, *sycN*, *yscB* and *lcrG* deletion mutants measured using a phosphorylatable
513 peptide tag and phosphospecific antibodies. *Molecular Microbiology*. 47(3), 807-823.
514 <https://doi.org/10.1046/j.1365-2958.2003.03343.x>.
- 515 Day J.B., Plano G.V., 1998. A complex composed of SycN and YscB functions as a specific chaperone
516 for YopN in *Yersinia pestis*. *Molecular microbiology*. 30(4), 777-788. [https://doi.org/](https://doi.org/10.1046/j.1365-2958.1998.01110.x)
517 [10.1046/j.1365-2958.1998.01110.x](https://doi.org/10.1046/j.1365-2958.1998.01110.x).
- 518 Deshmukh S., Kania P.W., Chettri J.K., Skov J., Bojesen A.M., Dalsgaard I., Buchmann K., 2013. Insight
519 from molecular, pathological, and immunohistochemical studies on cellular and humoral
520 mechanisms responsible for vaccine-induced protection of rainbow trout against *Yersinia ruckeri*.
521 *Clinical and vaccine immunology*. 20(10), 1623-1641. <https://doi.org/10.1128/CVI.00404-13>.
- 522 Fletcher M., 1977. The effects of culture concentration and age, time, and temperature on bacterial
523 attachment to polystyrene. *Can J Microbiol*. 23(1), 1-6. <https://doi.org/10.1139/m77-001>.
- 524 Galán J.E., Collmer A., 1999. Type III secretion machines: bacterial devices for protein delivery into host
525 cells. *Science*. 284(5418), 1322-1328. <https://doi.org/10.1126/science.284.5418.1322>.
- 526 Guillon H., Eb F., Mammeri H., 2010. Characterization of CSP-1, a novel extended-spectrum β-
527 lactamase produced by a clinical isolate of *Campylobacter sputigena*. *Antimicrobial agents and*
528 *chemotherapy*. 54(5), 2231-2234. <https://doi.org/10.1128/AAC.00791-09>.
- 529 Haldar S., 2012. *Vibrio* Related Diseases in Aquaculture and Development of Rapid and Accurate
530 Identification Methods. *Journal of Marine Science Research & Development*. 3(1), 1-7.
531 <https://doi.org/10.4172/2155-9910.S1-002>.
- 532 Kierek K., Watnick P.I., 2003. Environmental determinants of *Vibrio cholerae* biofilm development. *Appl*
533 *Environ Microbiol*. 69(9), 5079-5088. <https://doi.org/10.1128/aem.69.9.5079-5088.2003>.
- 534 Killeen K.P., V.J., 2001. DiRita, Live attenuated bacterial vaccines. *New Vaccine Technol*. 151.
- 535 Lafferty K.D., Harvell C.D., Conrad J.M., Friedman C.S., Kent M.L., Kuris A.M., Powell E.N., Rondeau
536 D., Saksida S.M., 2015. Infectious diseases affect marine fisheries and aquaculture economics.
537 *Annual Review of Marine Science*. 7(1), 471-496. [https://doi.org/10.1146/annurev-marine-010814-](https://doi.org/10.1146/annurev-marine-010814-015646)
538 [015646](https://doi.org/10.1146/annurev-marine-010814-015646).
- 539 Lee K.K., Yu S.R., Liu P.C., 1997. Alkaline serine protease is an exotoxin of *Vibrio alginolyticus* in
540 kuruma prawn, *Penaeus japonicus*. *Curr Microbiol*. 34(2), 110-117. [https://doi.org/](https://doi.org/10.1007/s002849900153)
541 [10.1007/s002849900153](https://doi.org/10.1007/s002849900153).
- 542 Li J., Mo Z.L., Li G.Y., Xiao P., Huang J., 2015. Generation and evaluation of virulence attenuated

543 mutants of *Edwardsiella tarda* as vaccine candidates to combat edwardsiellosis in flounder
544 (*Paralichthys olivaceus*). *Fish & shellfish immunology*. 43(1), 175-180. [https://doi.org/](https://doi.org/10.1016/j.fsi.2014.12.018)
545 10.1016/j.fsi.2014.12.018.

546 Li N.Q., Yang Z.H., Bai J.J., Fu X.Z., Liu L.H., Shi C.B., Wu S.Q., 2010. A shared antigen among *Vibrio*
547 species: outer membrane protein-OmpK as a versatile *Vibriosis* vaccine candidate in Orange-spotted
548 grouper (*Epinephelus coioides*). *Fish & shellfish immunology*. 28(5-6), 952-956.
549 <https://doi.org/10.1016/j.fsi.2010.02.010>.

550 Li P., Rivera-Cancel G., Kinch L.N., Salomon D., Tomchick D.R., Grishin N.V., Orth K., 2016. Bile salt
551 receptor complex activates a pathogenic type III secretion system. *Elife* 5, e15718.
552 <https://doi.org/10.7554/eLife.15718>.

553 Li W.X., Yao Z.J., Sun L.N., Hu W.J., Cao J.J., Lin W.X., Lin X.M., 2016. Proteomics analysis reveals a
554 potential antibiotic cocktail therapy strategy for *Aeromonas hydrophila* infection in biofilm. *Journal*
555 *of proteome research*. 15(6), 1810-1820. <https://doi.org/10.1021/acs.jproteome.5b01127>.

556 López J.R., De La Roca E., Núñez S., De La Herran R., Navas J.I., Manchado M., Herrera M., Toranzo
557 A.E., 2009. Identification of *Vibrio harveyi* isolated from diseased cultured wedge sole
558 *Dicologlossa cuneata*. *Diseases of Aquatic Organisms*. 84(3), 209-217. [https://doi.org](https://doi.org/10.3354/dao02045)
559 /10.3354/dao02045.

560 Mahbub K.R., Paul K.P., Ahmed M.M., 2011. Prevalence of *Vibrio* spp and antibiogram of isolates from
561 shrimp rearing ponds in Bangladesh. *Journal of Advanced Scientific Research*. 2(4), 74-80.

562 Millikan D.S., Ruby E.G., 2004. *Vibrio fischeri* flagellin A is essential for normal motility and for
563 symbiotic competence during initial squid light organ colonization. *J. Bacteriol*. 186(13), 4315-4325.
564 <https://doi.org/10.1128/JB.186.13.4315-4325.2004>.

565 Nguyen L., Paulsen I.T., Tchieu J., Hueck C.J., Saier Jr M.H., 2000. Phylogenetic analyses of the
566 constituents of type III protein secretion systems. *J. Mol. Microbiol. Biotechnol*. 2(2), 125-144.

567 Nydam S.D., Shah D.H., Call D.R., 2014. Transcriptome analysis of *Vibrio parahaemolyticus* in type III
568 secretion system 1 inducing conditions. *Front Cell Infect Microbiol*. 4, 1. [https://](https://doi.org/10.3389/fcimb.2014.00001)
569 doi.org/10.3389/fcimb.2014.00001.

570 Pang H.Y., Qiu M.S., Zhao J.M., Hoare R., Monaghan S.J., Song D.W., Chang Y.S., Jian J.C., 2018.
571 Construction of a *Vibrio alginolyticus* hopPmaJ (hop) mutant and evaluation of its potential as a
572 live attenuated vaccine in orange-spotted grouper (*Epinephelus coioides*). *Fish & shellfish*
573 *immunology*. 76, 93-100. <https://doi.org/10.1016/j.fsi.2018.02.012>.

574 Parsek M.R., Singh P.K., 2003. Bacterial biofilms: an emerging link to disease pathogenesis. *Annu Rev*
575 *Microbiol*. 57(1), 677-701. <https://doi.org/10.1146/annurev.micro.57.030502.090720>.

576 Reed L.J. Muench H., 1938. A simple method of estimating fifty per cent endpoints. *American Journal*
577 *of Epidemiology*. 27(3), 493-497. <https://doi.org/10.1093/oxfordjournals.aje.a118408>.

578 Sadok K., Mejdí S., Nourhen S., Amina B., 2013. Phenotypic characterization and RAPD fingerprinting
579 of *Vibrio parahaemolyticus* and *Vibrio alginolyticus* isolated during Tunisian fish farm outbreaks.
580 *Folia Microbiol*. 58(1), 17-26. <https://doi.org/10.1007/s12223-012-0174-x>.

581 Spaeth K.E., Chen Y.S., Valdivia R.H., 2009. The Chlamydia type III secretion system C-ring engages a
582 chaperone-effector protein complex. *PLoS pathogens*. 5(9). [https://doi.org/](https://doi.org/10.1371/journal.ppat.1000579)
583 10.1371/journal.ppat.1000579.

584 Stebbins C.E., Galán J.E., 2001. Maintenance of an unfolded polypeptide by a cognate chaperone in
585 bacterial type III secretion. *Nature*. 414(6859), 77-81. <https://doi.org/10.1038/35102073>.

586 Sullivan C., Kim C.H., 2008. Zebrafish as a model for infectious disease and immune function. *Fish &*

587 shellfish immunology. 25(4), 341-350. <https://doi.org/10.1016/j.fsi.2008.05.005>.

588 Verstraeten N., Braeken K., Debkumari B., Fauvart M., Fransaer J., Vermant J., Michiels J., 2008. Living
589 on a surface: swarming and biofilm formation. *Trends Microbiol.* 16(10), 496-506.
590 <https://doi.org/10.1016/j.tim.2008.07.004>.

591 Wang J., Zou L.L., Li A.X., 2014. Construction of a *Streptococcus iniae* sortase A mutant and evaluation
592 of its potential as an attenuated modified live vaccine in Nile tilapia (*Oreochromis niloticus*). *Fish
593 & shellfish immunology.* 40(2), 392-398. <https://doi.org/10.1016/j.fsi.2014.07.028>.

594 Wang Q.Y., Liu Q., Cao X.D., Yang M.J., Zhang Y.X., 2008. Characterization of two TonB systems in
595 marine fish pathogen *Vibrio alginolyticus*: their roles in iron utilization and virulence. *Archives of
596 microbiology.* 190(5), 595-603. <https://doi.org/10.1007/s00203-008-0407-1>.

597 Watnick P.I., Lauriano C.M., Klose K.E., Croal L., Kolter R., 2001. The absence of a flagellum leads to
598 altered colony morphology, biofilm development and virulence in *Vibrio cholerae* O139. *Mol
599 Microbiol.* 39(2), 223-35. <https://doi.org/10.1046/j.1365-2958.2001.02195.x>.

600 Wattiau P., Bernier B., Deslée P., Michiels T., Cornelis G.R., 1994. Individual chaperones required for
601 Yop secretion by *Yersinia*. *Proceedings of the National Academy of Sciences.* 91(22), 10493-10497.
602 <https://doi.org/10.1073/pnas.91.22.10493>.

603 Wattiau P., Woestyn S., Cornelis G.R., 1996. Customized secretion chaperones in pathogenic bacteria.
604 *Molecular microbiology.* 20(2), 255-262. <https://doi.org/10.1111/j.1365-2958.1996.tb02614.x>.

605 Wei G.B., Cai S.H., Wu Y.Z., Ma S.H., Huang Y.C., 2020. Immune effect of *Vibrio harveyi* formalin-
606 killed cells vaccine combined with chitosan oligosaccharide and astragalus polysaccharides in ♀
607 *Epinephelus fuscoguttatus* × ♂ *Epinephelus lanceolatus*. *Fish & shellfish immunology.* 98, 186-192.
608 <https://doi.org/10.1016/j.fsi.2020.01.015>.

609 Windle H.J., Kelleher D., 1997. Identification and characterization of a metalloprotease activity from
610 *Helicobacter pylori*. *Infect Immun.* 65(8), 3132-3137. <https://doi.org/10.1128/IAI.65.8.3132-3137.1997>.

612 Xiao J.F., Chen T., Liu B., Yang W.Z., Wang Q.Y., Qu J.B., Zhang Y.X., 2013. *Edwardsiella tarda* mutant
613 disrupted in type III secretion system and chorismic acid synthesis and cured of a plasmid as a live
614 attenuated vaccine in turbot. *Fish & Shellfish immunology.* 35(3), 632-641.
615 <https://doi.org/10.1016/j.fsi.2013.05.022>.

616 Xie Z.Y., Hu C.Q., Chen C., Zhang L.P., Ren C.H., 2005. Investigation of seven *Vibrio* virulence genes
617 among *Vibrio alginolyticus* and *Vibrio parahaemolyticus* strains from the coastal mariculture
618 systems in Guangdong, China. *Lett Appl Microbiol.* 41(2), 202-207. <https://doi.org/10.1111/j.1472-765X.2005.01688.x>.

620 Xu Z.N., Wang Y., Han Y., Chen J.X., Zhang X.H., 2011. Mutation of a novel virulence-related gene
621 *mltD* in *Vibrio anguillarum* enhances lethality in zebra fish. *Research in microbiology.* 162(2), 144-
622 150. <https://doi.org/10.1016/j.resmic.2010.08.003>.

623 Yao G., Tan Y.X., Zou W.Z., Xu X.J., Xing Y.L., Ji R.X., Zheng T.L., Yan Q.P., 2012. Characteristics of
624 *Vibrio alginolyticus* biofilm formation. *Fisheries Science.* 31(2), 73-78. <https://doi.org/10.16378/j.cnki.1003-1111.2012.02.003>.

626 Young G.M., Smith M.J., Minnich S.A., Miller V.L., 1999. The *Yersinia enterocolitica* motility master
627 regulatory operon, *flhDC*, is required for flagellin production, swimming motility, and swarming
628 motility. *Journal of bacteriology.* 181(9), 2823-2833. <https://doi.org/10.1128/JB.181.9.2823-2833.1999>.

629

630 Yuan Y.H., Pang H.Y., Zhou Z.J., Song D.W., Ding Y., Jian J.C., Wu Z.H., 2016. Construction of Live

631 Attenuated Vaccine against *Vibrio alginolyticus* and the Evaluation on Its Immunoprotection Effect.
632 *Animal Husbandry and Feed Science*. 8(02), 85-89+93. [https://doi.org/](https://doi.org/10.19578/j.cnki.ahfs.2016.02.007)
633 [10.19578/j.cnki.ahfs.2016.02.007](https://doi.org/10.19578/j.cnki.ahfs.2016.02.007).

634 Zhang X.C., Qi Z.Z., Du Z.M., Bi Y.J., Zhang Q.W., Tan Y.F., Yang H.Y., Xin Y.Q., Yang R.F., Wang
635 X.Y., 2013. A live attenuated strain of *Yersinia pestis* Δ yscB provides protection against bubonic
636 and pneumonic plagues in mouse model. *Vaccine*. 31(22), 2539-2542.
637 <https://doi.org/10.1016/j.vaccine.2013.03.054>.

638 Zhao Z., Chen C., Hu C.Q., Ren C.H., Zhao J.J., Zhang L.P., Jiang X., Luo P., Wang Q.B., 2010. The
639 type III secretion system of *Vibrio alginolyticus* induces rapid apoptosis, cell rounding and osmotic
640 lysis of fish cells. *Microbiology*. 156(9), 2864-2872. [https://doi.org/ 10.1099/mic.0.040626-0](https://doi.org/10.1099/mic.0.040626-0).

641 Zhou S.H., Tu X.T., Pang H.Y., Hoare R., Monaghan S.J., Luo J.J., Jian J.C., 2020. A T3SS Regulator
642 Mutant of *Vibrio alginolyticus* Affects Antibiotic Susceptibilities and Provides Significant
643 Protection to *Danio rerio* as a Live Attenuated Vaccine. *Frontiers in Cellular and Infection*
644 *Microbiology*. 10, 183. <https://doi.org/10.3389/fcimb.2020.00183>.

645 Zhou Z.J., Pang H.Y., Ding Y., Cai J., Huang Y.C., Jian J.C., Wu Z.H., 2013. VscO, a putative T3SS
646 chaperone escort of *Vibrio alginolyticus*, contributes to virulence in fish and is a target for vaccine
647 development. *Fish & shellfish immunology*. 35(5), 1523-1531. [https://doi.org/](https://doi.org/10.1016/j.fsi.2013.08.017)
648 [10.1016/j.fsi.2013.08.017](https://doi.org/10.1016/j.fsi.2013.08.017).

649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667

Table 1 Bacterial strains and plasmids used in this study

Strains, Plasmids	Relevant information	Source or references
<i>V. alginolyticus</i> HY9901	Wild type, isolated from diseased <i>Lutjanus</i> <i>sanguineus</i> off the Southern China coast	Cai et al., 2007

$\Delta vscB$	HY9901 carrying an in-frame deletion of <i>vcBS</i>	This study
C- <i>vscB</i>	HY9901 $\Delta vscB$ containing plasmid of pBAD33cm- <i>vscB</i>	This study
<i>E. coli</i> DH5 α	Competent cells	Sangon 2018
<i>E. coli</i> β 2163	Competent cells	This study
pMD18-T	Cloning vector, Ampr	TakaRa 2018
pBAD33-CM	<i>E. coli</i> -suicide vector	This study
pLP12	<i>E. coli</i> -suicide vector	This study

668

669

670

671

672

673

674

675

676

677

678 **Table 2 Sequences of primers used in this study.**

679

Primer name	Primer sequence(5'-3')	Accession number or references
Cloning primers		

vscB-F1	ATGTTAGATAAGATGATGAAATC	MG905226
vscB-R1	TCATGGTAACCACACTGTATG	
mutant construction		
<i>vscB</i> -MF1	GGAATCTAGACCTTGAGTCGGCTATCAGGGGAAGACACCAG	GU074526.1
<i>vscB</i> -MR1	TGTATGGTTGATTGTGTGGTTACCATCTTATCTAACATTTAACGCC	
<i>vscB</i> -MF2	GGCGTTAAATGTTAGATAAGATGGTGAACCACACAATCAACCATAC	
<i>vscB</i> MR2	ACAGCTAGCGACGATATGTC GGAGGACCCGCAAGATAGAC	
<i>vscB</i> -TF	ACTACATCAACTCTCGTCTGGGC	
<i>vscB</i> -TR	AACTTCTTTGCTAGACGCACTCG	
pLP-UF	GACACAGTTGTAAGTGGTCCA	
pLP-UR	CAGGAACACTTAACGGCTGAC	
Complement construction		
pBAD30-ZF	CTAGAGTCGACCTGCAGGCA	GU074526.1
pBAD30-ZR	AGCTCGAATTCGCTAGCCCA	
vscB-RF	TGGGCTAGCGAATTCGAGCTAGGAGGAATTCACCATGTTAGATAAGATGATG	
	TG	
vscB-RR	CATGCCTGCAGGTCGACTCTAGTCATGGTAACCACACTGTATG	
RP4-F2	CGAATTGGGTACCAGCGCTT	
RP4-R2	TACCGTCGACGCCGCCAGC	
pBAD30-mcf-TF	CCATAAGATTAGCGGATCCTACCT	
pBAD30-mcf-TR	CTTCTCTCATCCGCCAAAACAG	
16S-F	TTGCGAGAGTGAGCGAATCC	(Zhou et al.,2020)
16S -R	ATGGTGTGACGGGCGGTGTG	
VopN-F	TGAACTCGTTTCGGACTA	
VopN-R	ACTTCTGGACTCGCACT	
hop-F	CTTCGCTTTCGGTTTGCT	
hop-R	AATACCATCCACCCCTGT	
VscO-F	GAGCTGGAAACATTAAGACA	
VscO-R	TTGCTGCAACTGAACGAA	
VscN-F	TAGGCGAAGAAGGAATGG	
VscN-R	GCGATAGAAGTGGCAACAA	
VscK-F	GGCGTTATCTCCCGTTCC	
VscK-R	CTCCGCCACCATCAATA	
VscL-F	TACCACGGTGAGTGTAGTTC	
VscL-R	CGTAACCGACTTCAGGGA	
VopS-F	AGTTTTGGAAGTGTAGCG	
VopS-R	ACATTGCCTCTGTCATCG	
β -actin-F	GGACAGCTACGTTGGTGATGA	(Chenyanyan,2019)
β -actin-R	GGACAGCTACGTTGGTGATGA	
IL-1 β -F	TCTGGGCATCAAGGGCACACA	
IL-1 β -R	CCATGTCGCTGTTCGGATCGA	
TNF- α -F	GCCACAGGATCTGGCGCTACTC	

TNF- α -R	CTTCCGTCGCTGTCCTCATGTG
IgM-F	TACAGCCTCTGGATTAGACATTAG
IgM-R	CTGCTGTCTGCTGTTGTCTGTGGAG
CD8 α -F	GCTGGTGATTCTGCTGATTTG
CD8 α -R	GGACTTGGAGGATGACTTTAGG
MHC-I α -F	GCCGCCACGCTACAGGTTTCTA
MHC-I α -R	TCCATCGTGGTTGGGGATGATC

680

681

682

683

684

685

686

687

688

689

690

691

692

693

694

695

696

697

698 **Table 3 Characteristics of different strains**

Characteristics	HY9901	$\Delta vscB$	C- <i>vscB</i>
Activity of ECPase ^a	0.06 ± 0.02	0.06 ± 0.01	0.06 ± 0.02
Swarming(mm) ^b	32.22 ± 0.07	27.83 ± 0.06	31.18 ± 0.06
LD ₅₀ (cfu/mL) ^c	7.29 × 10 ⁴	1.69 × 10 ⁶ **	9.05 × 10 ⁴

699

700 **: $p < 0.01$.

701 Values are mean ± standard deviation for three trials.

702 ^a Bacteria were incubated in TSB for 18 h at 28°C.

703 ^b Swarming diameters were measured after 24 h incubation at 28°C on TSA
704 containing 0.3% agar plates.

705 ^c LD₅₀ were evaluated in pearl gentian grouper with an average weight of 20.0 ± 2g.

706

707

708

709

Table 4 Drug sensitivity test results of the HY9901, $\Delta vscB$ and *C-vscB*

Antibiotic	Dose (μg)	Bacteriostatic circle diameter (mm)					
		HY9901	Sensitivity	$\Delta vscB$	Sensitivity	<i>C-vscB</i>	Sensitivity ^a
Cefperazone	75	0	R	0	R	0	R
Oxacillin	1	0	R	0	R	0	R
Clindamycin	2	0	R	0	R	0	R
Ceftazidime	30	0	R	0	R	0	R
Penicillin	10U	0	R	0	R	0	R
Ampicillin	100	0	R	0	R	0	R
Caebenicilin	100	0	R	0	R	0	R
Cefazolin	30	8.0 \pm 0.2	R	0	R	0	R
Ceftriaxone	30	9.3 \pm 0.3	R	0	R	0	R
Cephadrine	30	0	R	0	R	0	R
Piperacillin	100	0	R	0	R	0	R
Cefuroxime	30	0	R	0	R	0	R
SMZ/TMP	23.75/ 1.25	0	R	0	R	0	R
Aboren	30	0	R	0	R	0	R
Vancomycin	30	0	R	0	R	10.0 \pm 0	R
Cephalexin	30	0	R	0	R	0	R
Polymyxin B	200IU	0	R	8.2 \pm 0.2	R	0	R
Norflxadcin	10	0	R	0	R	0	R
Ofloxacin	5	0	R	0	R	0	R
Ciprofloxacin	5	0	R	0	R	0	R
Amikacin	30	13.3 \pm 0.3	I	13.1 \pm 0.1	I	13.2 \pm 0.1	I
Minocycline	30	18.5 \pm 0.2	S	15.2 \pm 0.2	I	16.8 \pm 0.3	I
Tetracycline	30	13.5 \pm 0.2	I	13.0 \pm 0.2	I	14.8 \pm 0.2	I
Gentamicin	10	14.5 \pm 0.1	I	12.9 \pm 0.2	I	15.0 \pm 0.1	I
Furazolidone	300	10.5 \pm 0.4	R	10.0 \pm 0.1	R	10.0 \pm 0.1	R
Chloramphenicol	30	17.2 \pm 0.3	S	17.5 \pm 0.2	S	0	R
Kanamycin	30	14.1 \pm 0.2	I	12.3 \pm 0.2	R	14.5 \pm 0.2	I
Erythromycin	15	10.1 \pm 0.2	R	8.5 \pm 0.1	R	13.2 \pm 0.2	I
Doxycycline	30	16.5 \pm 0.3	S	14.2 \pm 0.1	I	16.6 \pm 0.2	S
Neomycin	30	14.2 \pm 0.3	I	12.6 \pm 0.3	I	0	R

711 ^aS(susceptible) I(intermediate) R(resistance)

712

713

714

715

716

717

718

719

720

721

722

723

724 **Figure Legends**

725 **Figure 1: PCR products following cloning by PCR of *V. alginolyticus* *vscB* gene**

726 M: DL2000 DNA marker; 1-2: PCR products of *vscB*

727

728 **Figure 2: Multiple sequence alignments of *V. alginolyticus* HY9901 T3SS protein**
729 **VscB.**

730 *V. alginolyticus* Accession NO.GU074526.1

731 *V. parahaemolyticus* Accession NO.KOY47612.1,

732 *V. campbellii* Accession NO.WP_045453226.1

733 *V. harveyi* Accession NO.WP_042605857.1

734 *V. tasmaniensis* Accession NO.WP_017096464.1

735 *V. jasicida* Accession NO.WP_045424028.1

736

737 **Figure 3: Construction and confirmation of the knockout mutant strain**
738 **HY9901 Δ *vscB* and C-*vscB***

739 (A)M: DL2000 marker; Lane 1. The 1396 bp fragment amplified from genomic DNAs of
740 HY9901 Δ *vscB* using primer pairs of *vscB*-TF / *vscB*-TR. Lane 2. *E. coli* β 2163 (pLP12-*vscB*)
741 using primer pairs of *vscB*-TF / *vscB*-TR. Lane 3. The 1771bp fragment amplified from genomic
742 DNAs of the wild-type strain HY9901 using primer pairs of *vscB*-TF / *vscB*-TR

743 (B) M: DL2000 marker; Lane 1-7. The 587 bp fragment amplified from genomic DNAs of C-*vscB*
744 using primer pairs of pBAD-mcf-TF/pNAD-mcf-TR

745

746 **Figure 4: Transmission electron microscopy (TEM) of the morphological features**
747 **of *Vibrio alginolyticus* HY9901 (A) and HY9901 Δ *vscB* (B).**

748 A:HY9901 B:C-*vscB* C: Δ *vscB*

749

750 **Figure 5: Hereditary stability of *Vibrio alginolyticus* Δ *vscB***

751 M: DL 2 000 DNA marker;

752 1--4: The 974 bp fragment amplified from genomic DNAs of HY9901 Δ *vscB* using primer pairs of
753 *vscB*-MF1 / *vscB*-MR2

754

755 **Figure 6: Growth features of *Vibrio alginolyticus* HY9901, Δ *vscB* and C-*vscB***

756 Aliquots of cell culture were taken at various time points and measured for cell density at OD₆₀₀.

757

758 **Figure 7: Measurement of *Vibrio alginolyticus* biofilm by crystal violet ammonium**
759 **oxalate .**

760

761

762 **Figure 8: Expression of induced *Vibrio alginolyticus* HY9901 and HY9901 Δ *vscB***
763 **T3SS-related genes**

764 **By DMEM.**

765 HY9901 Δ *vscB* had decreased the expression of *vopN*($p < 0.01$), *vscO*($p < 0.05$), while increase the
766 expression of *vopS*($p < 0.01$), *vscK*($p < 0.01$), *vscL*($p < 0.01$), *hop*($p < 0.05$), and *vscN*($p < 0.05$).

767

768 **Figure 9: The most enriched GO terms of differentially expressed genes**

769

770 **Figure 10 Propagation of HY9901 Δ vscB in grouper kidney (A) and spleen (B) following i.p.**
771 **injection with 100 μ L 1 \times 10⁵cfu mL⁻¹ Δ vscB. Control fish were i.p. injection with 100 μ L sterile**
772 **PBS. The number of viable bacteria was shown as the mean \pm standard of three samples.**

773

774 **Figure 11: Survival in groups vaccinated with HY9901 Δ vscB and PBS following**
775 **challenge with *Vibrio alginolyticus* HY9901.**


776 Control group were injected intraperitoneally with PBS.

777

778 **Figure 12: Comparative analysis of the expression of immune-related genes in liver**
779 **and spleen of grouper given the live attenuated HY9901 Δ vscB *Vibrio alginolyticus***
780 **vaccine vs. unvaccinated grouper.**

781 A: liver of grouper B: spleen of grouper

782 The liver and spleen of grouper were sampled at 1 day before challenge, and the mRNA level of
783 each immune-related gene was normalized to that of β -actin expression. Bars represent the mean
784 relative expression of three biological replicates and error bars represent standard deviation. The
785 group vaccinated with the mutant strain HY9901 Δ vscB had significantly increased expression of
786 MHC-I, TNF- α , IgM, and CD8 α genes both in liver and spleen compared to control fish injected
787 with PBS(p<0.01).



789

790

791 Figure 1

792

793

794

795

796

797

798

799

800

801

802

803

804

805

806

807

808

809

810

811

812

813

814

815

816

817

818

819 *V. alginolyticus* : MLDKMMKSLAEALKVGDFIASENGSYNIEVDQLSLTIHQASWFLWBAALPFQFKEHLDYQREQALQRCMQLS : 73

820 *V. parahaemolyticus* : MLDKMMKSLAEALKVGDFIASENGSYNIEVDQLSLTIHQASWFLWBAALPFQFKEHLDYQREQALQRCMQLS : 73

821 *V. campbellii* : MLDQMMKSLAATLGVGDFIASNNGSYDIEVDQMLNLIHQSSWFLWETVLPFQFQEQHLDYQREQALKHCMQLS : 73

822 *V. harveyi* : MLDQMMKSLAATLGVGDFIASNNGSYDIEVDQMLNLIHQSSWFLWETVLPFQFQEQHLDYQREQALKHCMQLS : 73

823 *V. tasmaniensis* : MLDKMMKSLAEALREVGDFIASNNGSYDIEVDQMLNLIHQSSWFLWETVLPFYFESLDFQKREQALKHCMQLS : 73

824 *V. jasicida* : MLDQMMKSLAATLGVGDFIASNNGSYDIEVDQMLNLIHQSSWFLWETVLPFQFQEQHLDYQREQALKHCMQLS : 73

825

identity

826 *V. alginolyticus* : LKTIREDGGVLTINDQQLILQSKVRIEDCSYVERFSALLSKHVNLCBRYTALLLEQARVNHTINHTVWLP : 142 100%

827 *V. parahaemolyticus* : LKTIREDGCVLTANDQQLILQSKVRIEDCSIEELFSSLLSKHVNLCBRYMALLEQARVNHTINHTVWLP : 142 91%

828 *V. campbellii* : LKTLRDTSSSTLTVNDNEQLIVQGKMMESATIEALCAQLSQHVNLEVEQFSGVLEHQRVNHTVSHSIVWIP : 142 61%

829 *V. harveyi* : LKTLRDTSSSTLTVNDNEQLIVQGKMMESVITIEALCAQLSQHVNLEVEQFSGVLEHQRVNHTVSHSIVWIP : 142 61%

830 *V. tasmaniensis* : LKTLRDTRSTLTVNDKEQLIMQCKMMESATIEELCTQLAQHVNLEVEQFNDLLEHQRVNHTVSHSIVWIP : 142 61%

831 *V. jasicida* : LKTLRDTSSSTLTVNDNEQLIVQGKMMESVITIEALCAQLSQHVNLEVEQFSGVLEHQRVNHTVSHSIVWIP : 142 60%

832 **Figure 2**

833

834

835

836

837

838

839

840

841


842

843

844


845

846



847

848



849

850

851

852 Figure 3

853

854

855

856

857

858

859

860

861

862

863

864


865

866

867

868

869



870 Figure 4

871

872

873

874

875

876

877

878

879

880

881

882

883

884

885

886

887

888

889

890

891

892

893

894

895

896

897


898

899

900

901

902
903




904

Figure 5

905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934


935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952



953 Figure 6

954
955
956
957
958
959
960
961
962
963
964

965



966

967 Figure 7

968

969

970

971

972

973

974

975

976

977

978

979

980

981

982

983

984

985

986

987

988

989

990

991


992

993

994

995

996
997
998
999




1000

Figure 8

1001
1002
1003
1004
1005
1006
1007
1008
1009
1010
1011
1012
1013
1014
1015
1016
1017
1018
1019
1020
1021
1022
1023
1024
1025
1026

1027
1028
1029
1030




1031
1032
1033
1034
1035
1036
1037
1038
1039
1040
1041
1042
1043
1044
1045
1046
1047
1048
1049

Figure 9

1050

A




1051

1052

1053

B



1054

1055

1056

1057

1058

1059 Figure 10

1060

1061

1062

1063


1064

1065

1066


1067

1068
1069
1070
1071
1072
1073
1074
1075




1076
1077
1078
1079
1080
1081
1082
1083
1084
1085
1086
1087
1088
1089

Figure 11



1090



1091

1092 Figure 12